Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

Brian I. Rini, MD, discusses the mechanism of action of tivozanib in relapsed/refractory renal cell carcinoma.

Wade T. Iams, MD, discusses the efficacy and safety of lurbinectedin in patients with small cell lung cancer, the impact of its approval on the paradigm, and remaining questions regarding its use.

Cathy Eng, MD, FACP, FASCO, discusses the rising incidence of early-onset colorectal cancer.

Douglas B. Johnson, MD, discusses the risks and benefits associated with anti–PD-1 therapy in patients with stage III resected melanoma.

Carlos del Rio, MD, discusses the reactogenicity of the COVID-19 vaccines.

Cathy Eng, MD, FACP, FASCO, discusses the ongoing phase 3 FRESCO-2 trial in metastatic colorectal cancer.

Cathy Eng, MD, FACP, FASCO, discusses the potential of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic colorectal cancer.

Kristen K. Ciombor, MD, MSCI, discusses responses achieved with preoperative chemoradiation in patients with rectal cancer.

Kristen K. Ciombor, MD, MSCI, discusses sequencing treatment options for patients with locally advanced rectal cancer.

Kristen K. Ciombor, MD, MSCI, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic gastric cancer.

The scope of adult nonmalignant hematology can be broad and includes thrombotic and hemorrhagic disorders, transfusion medicine, hemoglobin disorders including sickle cell disease and thalassemia, anemia, thrombocytopenia, leukocytosis, leukopenia, and disorders of iron metabolism.

In our exclusive interview, Dr. Powles and Dr. Rini provide insight into an analysis of the phase 3 IMvigor010 study and its implications for circulating tumor DNA as a biomarker in urothelial cancer and beyond.

Jordan D. Berlin, MD, discusses the unmet needs in pancreatic cancer treatment and ongoing research efforts with nanoliposomal irinotecan.

Stephen A. Strickland, MD, BS, MS, MSCI, relays insightful questions from the audience to the speakers, who provided insight into how they are navigating the evolving treatment landscape of hematologic malignancies.

Cathy Eng, MD, FACP, FASCO, discusses the features of high-risk colorectal cancer.

Cathy Eng, MD, FACP, FASCO, discusses ​contraindications for oxaliplatin-based therapy in colorectal cancer.

Cathy Eng, MD, FACP, FASCO, discusses the role of adjuvant chemotherapy in colorectal cancer.

Douglas B. Johnson, MD, MSCI, discusses his research examining the impact of body composition on outcomes from anti–PD-1 with or without anti–CTLA-4 therapies in melanoma and other biomarkers under exploration.

Laura Goff, MD, discusses the need to identify novel targets in hepatocellular carcinoma.

In recent years, great progress has been made in understanding the genetics of metastatic prostate cancer which has translated into the development of new precision therapies.

Vanderbilt-Ingram Cancer Center received an overall “exceptional” score for its research impact and excellence in patient care. This achievement merits renewed funding from the National Cancer Institute and places it once again in a top group of NCI Comprehensive Cancer Centers.

Although most younger patients received diagnoses of cancer of the rectum or distal colon, incidence rates are increasing across all colorectal anatomic subsites.

Douglas B. Johnson, MD, MSCI, discusses the need to identify novel biomarkers in melanoma.

Leora Horn, MD, MSc, FRCPC, discusses the role of mobocertinib in patients with non​–small cell lung cancer.

Douglas B. Johnson, MD, MSCI, discusses the limitations of biomarkers in melanoma.

Jordan D. Berlin, MD, discusses the importance of more data and more effective treatment regimens in metastatic pancreatic cancer, despite the number of treatment options currently available.

David F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.

David F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.

Eric Shinohara, MD, MSCI, discusses the potential to combine stereotactic body radiotherapy with immunotherapy in prostate cancer.

Eric Shinohara, MD, MSCI, discusses radiation therapy considerations for patients with prostate cancer.